CircNUP50 is a Novel Therapeutic Target That Promotes Cisplatin Resistance in Ovarian Cancer by Modulating P53 Ubiquitination

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2024 Jan 19

PMID 38243224

Authors

Yunshu Zhu

Leilei Liang

Yuxi Zhao

Jian Li

Jia Zeng

Yihang Yuan

Ning Li

Lingying Wu

Affiliations

Soon will be listed here.

Abstract

Background: Most patients with ovarian cancer (OC) treated with platinum-based chemotherapy have a dismal prognosis owing to drug resistance. However, the regulatory mechanisms of circular RNA (circRNA) and p53 ubiquitination are unknown in platinum-resistant OC. We aimed to identify circRNAs associated with platinum-resistant OC to develop a novel treatment strategy.

Methods: Platinum-resistant circRNAs were screened through circRNA sequencing and validated using quantitative reverse-transcription PCR in OC cells and tissues. The characteristics of circNUP50 were analysed using Sanger sequencing, oligo (dT) primers, ribonuclease R and fluorescence in situ hybridisation assays. Functional experimental studies were performed in vitro and in vivo. The mechanism underlying circNUP50-mediated P53 ubiquitination was investigated through circRNA pull-down analysis and mass spectrometry, luciferase reporters, RNA binding protein immunoprecipitation, immunofluorescence assays, cycloheximide chase assays, and ubiquitination experiments. Finally, a platinum and si-circNUP50 co-delivery nanosystem (Psc@DPP) was constructed to treat platinum-resistant OC in an orthotopic animal model.

Results: We found that circNUP50 contributes to platinum-resistant conditions in OC by promoting cell proliferation, affecting the cell cycle, and reducing apoptosis. The si-circNUP50 mRNA sequencing and circRNA pull-down analysis showed that circNUP50 mediates platinum resistance in OC by binding p53 and UBE2T, accelerating p53 ubiquitination. By contrast, miRNA sequencing and circRNA pull-down experiments indicated that circNUP50 could serve as a sponge for miR-197-3p, thereby upregulating G3BP1 to mediate p53 ubiquitination, promoting OC platinum resistance. Psc@DPP effectively overcame platinum resistance in an OC tumour model and provided a novel idea for treating platinum-resistant OC using si-circNUP50.

Conclusions: This study reveals a novel molecular mechanism by which circNUP50 mediates platinum resistance in OC by modulating p53 ubiquitination and provides new insights for developing effective therapeutic strategies for platinum resistance in OC.

Citing Articles

Recent advances and perspectives on the development of circular RNA cancer vaccines.

Gong Z, Hu W, Zhou C, Guo J, Yang L, Wang B NPJ Vaccines. 2025; 10(1):41.

PMID: 40025038 PMC: 11873252. DOI: 10.1038/s41541-025-01097-x.

Circular RNAs in cancer.

Guo Y, Huang Q, Heng Y, Zhou Y, Chen H, Xu C MedComm (2020). 2025; 6(2):e70079.

PMID: 39901896 PMC: 11788016. DOI: 10.1002/mco2.70079.

Circular RNA circAGAP1 promotes sunitinib sensitivity in renal cell carcinoma via sponging multiple PDGFR-targeted miRNAs.

Lv Q, Wang G, Hong Y, Zhu T, Qin S, Sun S Oncol Res. 2025; 33(2):407-420.

PMID: 39866227 PMC: 11754003. DOI: 10.32604/or.2024.047698.

Unraveling the Role of Ubiquitin-Conjugating Enzyme UBE2T in Tumorigenesis: A Comprehensive Review.

Gao C, Liu Y, Yu J, Wang R, Shi J, Chen R Cells. 2025; 14(1.

PMID: 39791716 PMC: 11719737. DOI: 10.3390/cells14010015.

O-GlcNAcylation in ovarian tumorigenesis and its therapeutic implications.

Xia L, Mei J, Huang M, Bao D, Wang Z, Chen Y Transl Oncol. 2024; 51:102220.

PMID: 39616984 PMC: 11647086. DOI: 10.1016/j.tranon.2024.102220.

References

Millstein J, Budden T, Goode E, Anglesio M, Talhouk A, Intermaggio M . Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol. 2020; 31(9):1240-1250. PMC: 7484370. DOI: 10.1016/j.annonc.2020.05.019. View

Yin Y, Li J, Rong J, Zhang B, Wang X, Han H . Circ_0067934 reduces JNK phosphorylation through a microRNA-545-3p/PPA1 axis to enhance tumorigenesis and cisplatin resistance in ovarian cancer. Immunopharmacol Immunotoxicol. 2022; 44(2):261-274. DOI: 10.1080/08923973.2022.2038193. View

Wang H, Luo Y, Ran R, Li X, Ling H, Wen F . IDO1 Modulates the Sensitivity of Epithelial Ovarian Cancer Cells to Cisplatin through ROS/p53-Dependent Apoptosis. Int J Mol Sci. 2022; 23(19). PMC: 9569641. DOI: 10.3390/ijms231912002. View

Nokhostin F, Azadehrah M, Azadehrah M . The multifaced role and therapeutic regulation of autophagy in ovarian cancer. Clin Transl Oncol. 2022; 25(5):1207-1217. DOI: 10.1007/s12094-022-03045-w. View

Zhu W, Huang H, Feng Y, Zhan L, Yang J, Zhu L . Hypoxia-induced miR-9 expression promotes ovarian cancer progression via activating PI3K/AKT/mTOR/GSK3β signaling pathway. Neoplasma. 2023; 70(2):216-228. DOI: 10.4149/neo_2023_221103N1079. View

Oi N, Yuan J, Malakhova M, Luo K, Ryu J, Zhang L . Resveratrol induces apoptosis by directly targeting Ras-GTPase-activating protein SH3 domain-binding protein 1. Oncogene. 2014; 34(20):2660-71. PMC: 4286533. DOI: 10.1038/onc.2014.194. View

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Pineros M . Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2018; 144(8):1941-1953. DOI: 10.1002/ijc.31937. View

Wang Y, Luo X, Wu N, Liao Q, Wang J . SRC-3/TRAF4 facilitates ovarian cancer development by activating the PI3K/AKT signaling pathway. Med Oncol. 2023; 40(2):76. PMC: 9831961. DOI: 10.1007/s12032-022-01944-0. View

Pawar N, Buzza M, Duru N, Strong A, Antalis T . Matriptase drives dissemination of ovarian cancer spheroids by a PAR-2/PI3K/Akt/MMP9 signaling axis. J Cell Biol. 2023; 222(11). PMC: 10515437. DOI: 10.1083/jcb.202209114. View

10.

Mo Y, Wang Y, Zhang S, Xiong F, Yan Q, Jiang X . Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO2. Mol Cancer. 2021; 20(1):112. PMC: 8406723. DOI: 10.1186/s12943-021-01409-4. View

11.

Fraser M, Bai T, Tsang B . Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer. 2007; 122(3):534-46. DOI: 10.1002/ijc.23086. View

12.

Li C, Men C, Yang W, Chen R, Zhu J, Cheng Z . Repressing IRS1/2 by NT157 inhibits the malignant behaviors of ovarian cancer through inactivating PI3K/AKT/mTOR pathway and inducing autophagy. Kaohsiung J Med Sci. 2023; 39(4):377-389. DOI: 10.1002/kjm2.12652. View

13.

Sriramkumar S, Matthews T, Ghobashi A, Miller S, VanderVere-Carozza P, Pawelczak K . Platinum-Induced Ubiquitination of Phosphorylated H2AX by RING1A Is Mediated by Replication Protein A in Ovarian Cancer. Mol Cancer Res. 2020; 18(11):1699-1710. PMC: 7642062. DOI: 10.1158/1541-7786.MCR-20-0396. View

14.

Li H, Luo F, Jiang X, Zhang W, Xiang T, Pan Q . CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype. J Immunother Cancer. 2022; 10(3). PMC: 8919471. DOI: 10.1136/jitc-2021-004029. View

15.

Yang-Hartwich Y, Soteras M, Lin Z, Holmberg J, Sumi N, Craveiro V . p53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene. 2014; 34(27):3605-16. DOI: 10.1038/onc.2014.296. View

16.

Chen L, Yang L . Regulation of circRNA biogenesis. RNA Biol. 2015; 12(4):381-8. PMC: 4615371. DOI: 10.1080/15476286.2015.1020271. View

17.

Liang L, Zhu Y, Li J, Zeng J, Wu L . ALKBH5-mediated m6A modification of circCCDC134 facilitates cervical cancer metastasis by enhancing HIF1A transcription. J Exp Clin Cancer Res. 2022; 41(1):261. PMC: 9413927. DOI: 10.1186/s13046-022-02462-7. View

18.

Zhao Z, Ji M, Wang Q, He N, Li Y . Circular RNA Cdr1as Upregulates SCAI to Suppress Cisplatin Resistance in Ovarian Cancer via miR-1270 Suppression. Mol Ther Nucleic Acids. 2019; 18:24-33. PMC: 6726918. DOI: 10.1016/j.omtn.2019.07.012. View

19.

Chen J, Ning E, Wang Z, Jing Z, Wei G, Wang X . Docetaxel loaded mPEG-PLA nanoparticles for sarcoma therapy: preparation, characterization, pharmacokinetics, and anti-tumor efficacy. Drug Deliv. 2021; 28(1):1389-1396. PMC: 8245084. DOI: 10.1080/10717544.2021.1945167. View

20.

Jin L, Chun J, Pan C, Li D, Lin R, Alesi G . MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer Cell. 2018; 34(2):315-330.e7. PMC: 6092215. DOI: 10.1016/j.ccell.2018.06.012. View